Clinical Trials
14 trialsNCT00792948 2026-04-13
Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00776373 2025-11-05
UPCC 25406
Abramson Cancer Center at Penn Medicine
Phase 1/2 Terminated
NCT02722668 2025-07-04
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT05805605 2025-07-01
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT00544115 2025-06-10
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Phase 2 Active not recruiting
NCT01184885 2025-05-04
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT00105001 2019-10-30
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01116232 2019-03-26
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT00513474 2017-05-25
Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant
Massachusetts General Hospital
Phase 1 Completed
NCT00068302 2015-03-12
Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma
Children's Hospital of Philadelphia
Phase 1 Terminated
NCT00589563 2014-09-10
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00290472 2014-05-23
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00089037 2011-07-15
Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00317785 2010-05-07
Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases
Fred Hutchinson Cancer Center
Phase 2 Completed